早产儿视网膜病变:抗血管内皮生长因子治疗的演变
本文综述早产儿视网膜病变(ROP)从首次描述以来的演变,涵盖病理生理理解、诊断方法、破坏性治疗、抗VEGF治疗及支持治疗的变化,并讨论全球ROP表现的差异。抗VEGF药物可抑制病理性新生血管,同时通过引导视网膜内血管发育来扩展正常视网膜内血管生成,临床试验证据正在积累,目标为开发更少破坏性、保护视网膜和婴儿视力的治疗。
要点
- ROP已从影响约2个月早产儿演变为影响极早产儿。
- 全球ROP表现不同,新兴国家特征类似美国最初描述时。
- 抗VEGF药物抑制病理性血管生成并引导视网膜内血管发育。
核心结论
- ROP的目标是优化产前和围产期护理,提高全球诊断准确性并完善治疗策略。
- 抗VEGF药物用于抑制玻璃体内血管生成并促进先前无血管视网膜的血管化。
- 治疗需支持早产儿和视网膜的神经与血管发育。
研究设计与样本
- 文献综述与综合,纳入历史文章及关于病理生理风险因素、全球ROP、基础与临床科学(尤其抗VEGF机制和临床试验药物)的文献。
主要发现
- ROP已从影响约2个月早产儿演变为影响极早产儿。
- 全球ROP表现不同,新兴国家特征类似美国最初描述时。
- 治疗从破坏周边无血管视网膜以抑制血管生成刺激,演变为抗VEGF药物。
- 抗VEGF药物抑制病理性血管生成,但也通过引导视网膜内血管发育来扩展正常视网膜内血管生成。
- 临床试验证据正在积累,目标为开发更少破坏性、保护视网膜和婴儿视力的治疗。
临床怎么用
- 优化产前和围产期护理。
- 提高全球ROP诊断准确性。
- 完善治疗策略,包括使用抗VEGF药物抑制玻璃体内血管生成并促进无血管视网膜血管化。
- 治疗需支持早产儿和视网膜的神经与血管发育。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To discuss the evolution in retinopathy of prematurity since its first description as retrolental fibroplasia in the United States, including the changes in the understanding of pathophysiology; methods of diagnosis; destructive, anti-vascular endothelial growth factor (anti-VEGF), and supportive treatments; and differences in retinopathy of prematurity manifestations worldwide. The overall goal is to clarify retinopathy of prematurity currently and formulate questions to optimize future care. STUDY DESIGN: Literature review and synthesis. METHODS: Critical review and consideration of the literature with inclusion of historical articles and those regarding pathophysiologic risk factors, retinopathy of prematurity worldwide, basic and clinical science particularly regarding anti-VEGF mechanisms and agents tested in clinical trials. RESULTS: Retinopathy of prematurity has evolved from affecting infants approximately 2 months premature to affecting extremely premature infants. Worldwide, retinopathy of prematurity differs and, in emerging countries, has features similar to that experienced in the United States when retinopathy of prematurity first manifested. Treatments have evolved from destruction of the peripheral avascular retina to inhibit angiogenic stimuli to anti-VEGF agents, which inhibit pathologic angiogenesis but also extend normal intraretinal angiogenesis by ordering the development of intraretinal vessels. Clinical trial evidence is accruing with the goal to develop less destructive treatments to optimize vision and that are protective to the retina and infant. CONCLUSIONS: Goals for retinopathy of prematurity are to optimize prenatal and perinatal care, improve diagnostic acumen worldwide and refine treatment strategies, including with anti-VEGF agents, to inhibit intravitreal angiogenesis and facilitate vascularization of the previously avascular retina, which include supporting neural and vascular development of the premature infant and retina.
引用
- Hartnett ME. Retinopathy of Prematurity: Evolving Treatment With Anti-Vascular Endothelial Growth Factor. Am J Ophthalmol. 2020. PMID: 32450064. doi:10.1016/j.ajo.2020.05.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。